Edition:
United Kingdom

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

25.28USD
22 Jan 2018
Change (% chg)

$0.57 (+2.31%)
Prev Close
$24.71
Open
$24.86
Day's High
$25.42
Day's Low
$24.64
Volume
125,201
Avg. Vol
101,396
52-wk High
$26.43
52-wk Low
$15.57

Chart for

About

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $948.89
Shares Outstanding(Mil.): 38.39
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018

* ‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​

08 Jan 2018

BRIEF-Retrophin And Censa Pharmaceuticals Enter Into Strategic Collaboration To Advance Cnsa-001

* RETROPHIN AND CENSA PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE CNSA-001 FOR THE TREATMENT OF PHENYLKETONURIA (PKU)

05 Jan 2018

BRIEF-Retrophin Enters Into Future Acquisition Right, Joint Development Agreement With Censa Pharma

* RETROPHIN SAYS ON DEC 16, CO ENTERED INTO FUTURE ACQUISITION RIGHT, JOINT DEVELOPMENT AGREEMENT WITH CENSA PHARMA - SEC FILING

05 Jan 2018

BRIEF-Retrophin reports third quarter 2017 financial results

* Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S

07 Nov 2017

Martin Shkreli seeks to overturn part of his conviction

NEW YORK Former drug company executive Martin Shkreli on Friday asked a judge to throw out part of his criminal conviction, a day after prosecutors sought to have him jailed until his sentencing.

08 Sep 2017

UPDATE 1-Martin Shkreli seeks to overturn part of his conviction

NEW YORK, Sept 8 Former drug company executive Martin Shkreli on Friday asked a judge to throw out part of his criminal conviction, a day after prosecutors sought to have him jailed until his sentencing.

08 Sep 2017

BRIEF-Retrophin reports Q2 loss per share $0.34

* Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

09 Aug 2017

Jury in Martin Shkreli trial seeks clarity on 'fraudulent intent'

NEW YORK, Aug 1 Jurors in the trial of former drug company executive Martin Shkreli on Tuesday asked a judge to clarify the definition of "fraudulent intent," a key element of the case, in their first significant note since they began deliberating Monday morning.

01 Aug 2017

BRIEF-Retrophin commences patient dosing in international, registrational phase 3 trial of RE-024 in PKAN

* Retrophin commences patient dosing in international, registrational phase 3 trial of re-024 in pkan

25 Jul 2017

Earnings vs. Estimates